Hepatitis A virus antigen and Hepatitis B surface antigen (HAV-HBsAg)

The target "Immune system via presented Hepatitis A virus antigen and Hepatitis B surface antigen" refers to the combined antigenic components used in bivalent vaccines to elicit a protective immune response against both Hepatitis A (HAV) and Hepatitis B (HBV). The Hepatitis A component is generally derived from inactivated virus particles, while the Hepatitis B component consists of the recombinant surface antigen (HBsAg) (StatPearls, 2023). These antigens are recognized by the host's immune system, specifically by antigen-presenting cells (APCs), which process and display them to T and B lymphocytes (CDC, 2022). This interaction triggers the production of neutralizing antibodies—anti-HAV and anti-HBs—which provide long-term immunity by preventing viral entry into hepatocytes during subsequent exposures (WHO, 2023). This target is central to public health strategies aimed at reducing the incidence of viral hepatitis and its complications, such as cirrhosis and hepatocellular carcinoma (PubMed, 2021).

Other names

Hepatitis A and B vaccine antigensHAV/HBV antigensInactivated Hepatitis A virus and recombinant Hepatitis B surface antigenBivalent hepatitis A and B vaccine components

Active immunization through the induction of specific neutralizing antibodies against Hepatitis A virus and Hepatitis B virus.